» Articles » PMID: 28477315

Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?

Overview
Date 2017 May 7
PMID 28477315
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Lithium preparations have been successfully used to treat bipolar disorder (BD), and remain the best established long-term treatment for the disorder. In fact, lithium is a cornerstone of treatment to minimize the risk of recurrences and improve inter-episodic symptomatology. We reviewed the available evidence for the use of lithium in the treatment of BD, including its efficacy, limitations, and potential benefits also in consideration of the different formulations available. We also overviewed salient comparative aspects regarding the long-term alternative use of anticonvulsants, antidepressants, and antipsychotics in BD patients. The available evidence indicates that BD patients should be treated primarily with lithium, combined in some cases with antipsychotics especially in acute treatments, and sometimes, because of intolerance or inefficacy of lithium, with anticonvulsants. The use of adjunctive antidepressants should be limited to episodes of breakthrough depression. Lithium should be offered to the majority of BD patients as initial treatment especially when suicide ideation or behavior is present with adequate information about its long-term benefits and its potential side effects. Many patients can tolerate lithium without concomitant use of antidepressants, which may worsen the course of the illness or antipsychotics, which may cause severe long-term side effects.

Citing Articles

Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis.

Avrahami M, Liwinski T, Eckstein Z, Peskin M, Perlman P, Sarlon J Psychopharmacology (Berl). 2024; 241(9):1883-1894.

PMID: 38733528 DOI: 10.1007/s00213-024-06603-y.


Pseudodementia in Patients with Unipolar and Bipolar Disorders: A Case Series and Literature Review.

Elefante C, Brancati G, Acierno D, Pistolesi G, Ricciardulli S, Weiss F J Clin Med. 2024; 13(6).

PMID: 38541988 PMC: 10971625. DOI: 10.3390/jcm13061763.


From Unipolar to Bipolar: The Diagnostic Evolution in an Elderly Man.

Lu V, Zhang M, Tan G, Ying J Case Rep Psychiatry. 2023; 2023:6609793.

PMID: 37920866 PMC: 10620020. DOI: 10.1155/2023/6609793.


Lithium and Valproic Acid in Bipolar Disorders and Beyond.

Scarselli M Curr Neuropharmacol. 2023; 21(4):890.

PMID: 37203193 PMC: 10227910. DOI: 10.2174/1570159X2104230307123319.


The Nrf2 Pathway in Depressive Disorders: A Systematic Review of Animal and Human Studies.

Sani G, Margoni S, Brugnami A, Ferrara O, Bernardi E, Simonetti A Antioxidants (Basel). 2023; 12(4).

PMID: 37107192 PMC: 10135298. DOI: 10.3390/antiox12040817.


References
1.
Goldsmith D, Wagstaff A, Ibbotson T, Perry C . Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003; 63(19):2029-50. DOI: 10.2165/00003495-200363190-00009. View

2.
Pacchiarotti I, Bond D, Baldessarini R, Nolen W, Grunze H, Licht R . The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013; 170(11):1249-62. PMC: 4091043. DOI: 10.1176/appi.ajp.2013.13020185. View

3.
Albert U, De Cori D, Blengino G, Bogetto F, Maina G . [Lithium treatment and potential long-term side effects: a systematic review of the literature]. Riv Psichiatr. 2014; 49(1):12-21. DOI: 10.1708/1407.15620. View

4.
Yatham L, Kennedy S, Parikh S, Schaffer A, Beaulieu S, Alda M . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2012; 15(1):1-44. DOI: 10.1111/bdi.12025. View

5.
Malhi G, Tanious M, Das P, Berk M . The science and practice of lithium therapy. Aust N Z J Psychiatry. 2012; 46(3):192-211. DOI: 10.1177/0004867412437346. View